[go: up one dir, main page]

DE602004004259D1 - (6-(PHENOXY)-PYRIDOi3,4-DöPYRIMIDIN-2-YL)-AMIN DERIVATE ALS P38 KINASE INHIBITOREN ZUR BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN WIE RHEUMATOIDER ARTHRITIS - Google Patents

(6-(PHENOXY)-PYRIDOi3,4-DöPYRIMIDIN-2-YL)-AMIN DERIVATE ALS P38 KINASE INHIBITOREN ZUR BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN WIE RHEUMATOIDER ARTHRITIS

Info

Publication number
DE602004004259D1
DE602004004259D1 DE602004004259T DE602004004259T DE602004004259D1 DE 602004004259 D1 DE602004004259 D1 DE 602004004259D1 DE 602004004259 T DE602004004259 T DE 602004004259T DE 602004004259 T DE602004004259 T DE 602004004259T DE 602004004259 D1 DE602004004259 D1 DE 602004004259D1
Authority
DE
Germany
Prior art keywords
dopyrimidin
pyridoi3
phenoxy
treatment
rheumatoid arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004004259T
Other languages
English (en)
Other versions
DE602004004259T2 (de
Inventor
James Dewdney
Michael Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602004004259D1 publication Critical patent/DE602004004259D1/de
Application granted granted Critical
Publication of DE602004004259T2 publication Critical patent/DE602004004259T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004004259T 2003-04-16 2004-04-13 (6-(PHENOXY)-PYRIDOi3,4-DöPYRIMIDIN-2-YL)-AMIN DERIVATE ALS P38 KINASE INHIBITOREN ZUR BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN WIE RHEUMATOIDER ARTHRITIS Expired - Fee Related DE602004004259T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46322903P 2003-04-16 2003-04-16
US463229P 2003-04-16
PCT/EP2004/003883 WO2004091625A1 (en) 2003-04-16 2004-04-13 (6-(phenoxy)-pyrido`3,4-d! pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis

Publications (2)

Publication Number Publication Date
DE602004004259D1 true DE602004004259D1 (de) 2007-02-22
DE602004004259T2 DE602004004259T2 (de) 2007-11-15

Family

ID=33300055

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004004259T Expired - Fee Related DE602004004259T2 (de) 2003-04-16 2004-04-13 (6-(PHENOXY)-PYRIDOi3,4-DöPYRIMIDIN-2-YL)-AMIN DERIVATE ALS P38 KINASE INHIBITOREN ZUR BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN WIE RHEUMATOIDER ARTHRITIS

Country Status (16)

Country Link
US (2) US7189731B2 (de)
EP (1) EP1620105B1 (de)
JP (1) JP2006523640A (de)
KR (1) KR20060006037A (de)
CN (1) CN1774250A (de)
AR (1) AR044515A1 (de)
AU (1) AU2004229163A1 (de)
BR (1) BRPI0409405A (de)
CA (1) CA2520785A1 (de)
CL (1) CL2004000805A1 (de)
DE (1) DE602004004259T2 (de)
ES (1) ES2279361T3 (de)
MX (1) MXPA05010975A (de)
RU (1) RU2005135329A (de)
TW (1) TW200503722A (de)
WO (1) WO2004091625A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004020908A1 (de) * 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
US20090131430A1 (en) * 2004-11-23 2009-05-21 Palle Venkata P Pyrido'2,3-dipyrimidines as anti-inflammatory agents
RU2293559C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ подготовки к любрикантной терапии
RU2293560C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ лечения хронических гонартритов у больных остеоартрозом
ES2303758B1 (es) * 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
MX2011009034A (es) 2009-03-11 2011-09-22 Auckland Uniservices Ltd Formas de profarmaco de inhibidores de cinasa y su uso en la terapia.
JP5925680B2 (ja) * 2009-09-02 2016-05-25 オークランド ユニサーヴィスィズ リミテッド キナーゼインヒビター、そのプロドラッグ型および治療におけるそれらの使用
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
JP7012152B2 (ja) 2017-10-05 2022-02-10 フルクラム セラピューティクス，インコーポレイテッド Ｆｓｈｄの治療のためにｄｕｘ４および下流遺伝子発現を低減するｐ３８キナーゼ阻害剤
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1199768A (en) 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
JPS4936700A (de) * 1972-08-16 1974-04-05
US4672116A (en) 1985-12-20 1987-06-09 Ortho Pharmaceutical Corporation Substituted 5,6-dialkoxyquinazoline derivatives
US5084463A (en) 1989-12-11 1992-01-28 American Home Products Corporation N-quinolinyl alkyl-substituted 1-aryloxy-2-propanolamine and propylamine derivatives possessing class III antiarrhythmic activity
US20020061879A1 (en) 1996-02-02 2002-05-23 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
ES2384551T3 (es) 1997-03-05 2012-07-06 Sugen, Inc. Formulaciones para agentes farmacéuticos hidrófobos
US6313294B1 (en) 1998-02-04 2001-11-06 Development Center For Biotechnology Process for preparing amides
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
EP1235815A1 (de) 1999-11-22 2002-09-04 Warner-Lambert Company Chinazoline und ihre verwendung als cyclin-dependent kinase enzym- inhibitoren
EP1110552A1 (de) 1999-12-22 2001-06-27 Aventis Pharma S.A. Verwendung einer Verbingung mit hoher Affinität für den mitochondrialen Benzodiazepin Rezeptor in einem Arzneimittel zur Krebs-Therapie
AU2001245401A1 (en) 2000-03-01 2001-09-12 Sumitomo Pharmaceuticals Company, Limited Hydrazones and analogs as cholesterol lowering agents
HUP0300721A3 (en) 2000-07-26 2006-02-28 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity, process for producing them, pharmaceutical compositions containing them and use thereof
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
WO2002064594A2 (en) * 2001-02-12 2002-08-22 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
EP1389209B1 (de) 2001-04-24 2009-04-08 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
WO2002090360A1 (en) * 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
BR0313297A (pt) * 2002-08-06 2005-06-21 Hoffmann La Roche 6-alcóxi-pirido-pirimidinas como inibidores de p-38 map cinase

Also Published As

Publication number Publication date
US20070135459A1 (en) 2007-06-14
AU2004229163A1 (en) 2004-10-28
KR20060006037A (ko) 2006-01-18
CL2004000805A1 (es) 2005-02-04
EP1620105A1 (de) 2006-02-01
ES2279361T3 (es) 2007-08-16
WO2004091625A1 (en) 2004-10-28
RU2005135329A (ru) 2006-08-10
CN1774250A (zh) 2006-05-17
EP1620105B1 (de) 2007-01-10
JP2006523640A (ja) 2006-10-19
AR044515A1 (es) 2005-09-14
US7189731B2 (en) 2007-03-13
CA2520785A1 (en) 2004-10-28
TW200503722A (en) 2005-02-01
MXPA05010975A (es) 2005-11-28
DE602004004259T2 (de) 2007-11-15
BRPI0409405A (pt) 2006-04-25
US20040209903A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
DE602006010243D1 (de) 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
MEP52808A (en) Aminoheteroaryl compounds as protein kinase inhibitors
NZ542616A (en) P38 inhibitors and methods of use thereof
MY140291A (en) Sulfoximine-substituted pyrimidines for use as cd and/or vegf inhibitors, the production thereof and their use as drugs
CY1110746T1 (el) Ετεροαρωματικες ενωσεις κινολινης και χρηση αυτων ως αναστολεις pde10
ATE473980T1 (de) Triazolopyridazine als proteinkinase-inhibitoren
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
SE0301372D0 (sv) Novel compounds
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
SE0301373D0 (sv) Novel compounds
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
DE60332396D1 (de) PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN
GB0402137D0 (en) Novel compounds
EA200970738A1 (ru) Ингибиторы активности akt
DK1580188T3 (da) Forbindelser af arylurea som kinaseinhibitorer
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
CY1105686T1 (el) 2-(ΠΥΡΙΔΙΝ-2-ΥΛΑΜΙΝΟ)-ΠΥΡΙΔΟ[2,3-d]ΠΥΡΙΜΙΔΥΝ-7-ΟΝΕΣ
NO20070453L (no) Kondenserte heterocykliske kinase inhibitorer
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
NL1027811A1 (nl) Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1.
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
NL1025073C2 (nl) Indazoolverbindingen en farmaceutische preparaten voor het remmen van proteïnekinasen, en werkwijzen voor hun gebruik.
ATE362929T1 (de) Pyridinderivate als inhibitoren der raf-kinase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee